Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

IMPORTANCE: A blood test to determine whether to treat patients with metastatic castration-resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS) inhibitor or taxane is an unmet medical need. OBJECTIVE: To determine whether a validated assay for the nuclear-localized androgen re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Scher, Howard I., Graf, Ryon P., Schreiber, Nicole A., Jayaram, Anuradha, Winquist, Eric, McLaughlin, Brigit, Lu, David, Fleisher, Martin, Orr, Sarah, Lowes, Lori, Anderson, Amanda, Wang, Yipeng, Dittamore, Ryan, Allan, Alison L., Attard, Gerhardt, Heller, Glenn
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139066/
https://ncbi.nlm.nih.gov/pubmed/29955787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1621
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares